Phaseline

Targets › ACP3

ACP3 (Prostatic acid phosphatase): drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2031.

A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylated proteins. Has lipid phosphatase activity and inactivates lysophosphatidic acid in seminal plasma..; FUNCTION: [Isoform 2]: Tyrosine phosphatase that acts as a tumor suppressor of prostate cancer through dephosphorylation…. (UniProt, P15309)

Open in Phaseline: the race on ACP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
DendreonSipuleucel-T
Prostatic acid phosphatase binding agent
ACP3Phase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC); Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate AdenocarcinomaDec 2031

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC) (2) Prostate Cancer (1) Metastatic Castration-resistant Prostate Cancer (1) Metastatic Castration-Resistant Prostate Adenocarcinoma (1)

Modalities

other (1)

Companies

Dendreon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.